Broker’s call: Molbio Diagnostics (Buy)
Motilal Oswal
Molbio Diagnostics, a diagnostics technology company, has been building its business around the Truenat platform, which is a portable molecular testing system enabling rapid point-of-care testing without extensive infrastructure. The company's devices are deployed in over 90 countries, with a substantial installed base of 12,500+ units.
The company offers an extensive range of 43 assays covering 30 different diseases, tapping into a global market for POCT infectious-disease testing valued at $9.3 billion and projected to grow at a compound annual growth rate (CAGR) of around 23%.
Molbio's strategic advantage lies in its integrated Truenat ecosystem, which merges proprietary molecular diagnostic devices with a recurring test-kit franchise. This integrated approach allows the company to capture the expanding market of decentralized molecular diagnostics. The company's expansion is driven by three key factors: its growing installed base of Truenat devices, the increasing number of assays, and global scale-up efforts.
Additionally, as the company's utilization rate improves, operating leverage is expected to increase. Based on these projections, the analyst forecasts a 23% revenue CAGR, a 910 basis points margin expansion, and a 50% CAGR in the PAT market over the FY26-29 fiscal years.
The target price for Molbio Diagnostics is estimated at ₹1,800, calculated using a 45x 12-month forward earnings multiple. The analyst initiates coverage of Molbio with a Buy rating. However, there are certain risks associated with the company, such as customer concentration, the high revenue contribution of TB testing, potential delays in regulatory approvals, and slower-than-expected adoption of Truenat technology.
Rewritten by urgent.news; may contain errors — check the original.